icon-    folder.gif   Conference Reports for NATAP  
 
  21st Conference on Retroviruses and
Opportunistic Infections
Boston, MA March 3 - 6, 2014
Back grey_arrow_rt.gif
 
 
 
Switch from NNRTI plus FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated
 
 
  Reported by Jules Levin
21st Conference on Retroviruses and Opportunistic Infections
March 3-6, 2014
Boston, Massachusetts
 
A Pozniak,1 M Markowitz,2 A Mills,3 H Stellbrink,4 A Antela,5 P Domingo,6 P Girard,7 K Henry,8 W Garner,9 and B Guyer1Chelsea
and Westminster Hospital, London, UK; 2Aaron Diamond AIDS Research Center, NY, USA; 3Anthony Mills MD Inc., Los Angeles, CA, USA; 4ICH Study Center, Hamburg, Germany; 5Hospital Clinico Universitario, Santiago de Compostela, Spain; 6Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 7Hopital Saint-Antoine, Paris, France; 8Hennepin County Medical Center, Minneapolis, MN, USA; 9Gilead Sciences, Inc., Foster City, CA, USA

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif

CROI9.gif

CROI10.gif

CROI11.gif

CROI12.gif

CROI13.gif

CROI14.gif

CROI15.gif